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paroxetine (expected cost = $688 for 76 SFDs), for an incre-
mental cost effectiveness ratio of $2.79/SFD ($1004/Symptom-
free year). Paroxetine was dominated under the SOC perspective.
Total expected cost from the SOC perspective was $3676 and
$3529 for paroxetine and escitalopram, respectively. Sensitivity
analysis was conducted on upper and lower efﬁcacy boundaries,
yielding similar incremental cost-effectiveness results. CON-
CLUSION: Escitalopram is cost-saving in the treatment of GAD
under the SOC perspective in Canada, and appears to be cost-
effective under the MoH perspective.
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of ADHD (Hyperkinetic Disorder: ICD-10 F90.0, F90.1).
METHODS: Using the comprehensive claims database of the
ofﬁcial physicians’ organization of Nordbaden (KVNB, with an
insured population of 2.234m in 2003), n = 630 ADHD patients
age 20 and beyond were identiﬁed. The ADHD group was
matched with a non-ADHD cohort (n = 630) on a 1 :1 ratio
based on age and gender, and the rate of co-existent conditions
was compared between both groups. Chi-square statistics was
used to explore levels of signiﬁcance. RESULTS: The most preva-
lent psychiatric conditions associated with ADHD in adults
included depressive episodes (F32: prevalence 30.3%; relative
risk [RR] 7.1*** [p < 0.001]), recurrent depressive disorder
(F33: 14.3%, RR 12.9***), persistent mood disorders (F34:
7.0%, RR 11.0***), anxiety disorders (F41: 15.7%, RR
5.8***), adjustment disorders (F43: 18.9%; RR 6.6***), other
neurotic disorders (F48: 8.6%, RR 6.8***), speciﬁc personality
disorders (F60: 14.1%; RR 22.3***), other behavioral/emo-
tional disorders with onset in childhood/adolescence (F98: 9.0%;
RR 57.0***), mental/behavioral disorders due to substance use
(F19: 4.9%; RR 7.8***) or due to use of alcohol (F10: 4.6%;
RR 5.8***), and eating disorders (F50: 4.3%, RR 13.5***).
Non-psychiatric conditions associated with ADHD included
obesity, metabolic, infectious and allergic disorders, including
asthma bronchiale, and diseases of the ear and hearing loss but
not disorders of the eye and visual disturbances. Detailed analy-
ses by age and gender will be presented. CONCLUSIONS: These
data point to signiﬁcant comorbidity associated with ADHD in
grown-ups, thus underscoring the clinical relevance of the con-
dition. They provide a basis for further epidemiological research
and for analyses of the cost associated with ADHD in adult
patients.
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With reported prevalence rates of 2–10%, ADHD is one of the
most common disorders of childhood and adolescence. Only
recently, comorbidity has been recognized as one of the most
important aspects of the disorder. OBJECTIVES: To determine
real-world prevalence rates for psychiatric and non-psychiatric
comorbid conditions in children and adolescents with a diagno-
sis of ADHD according to ICD-10 criteria (Hyperkinetic
[Conduct] Disorder, HKD/HKCD, F90.0/F90.1), using the
Nordbaden claims database covering 2.238m insured persons in
South-Western Germany (82% of the regional population).
METHODS: A total of n = 11,245 ADHD patients age 19 or
less were identiﬁed. The ADHD group was matched with a non-
ADHD cohort (n = 11,228) on a 1 :1 ratio based on age and
gender, and the rate of co-existent conditions was compared
between both groups. Chi-square statistics was used to explore
levels of signiﬁcance. RESULTS: The most frequent psychiatric
comorbidities (in 20–40% of patients, each; all p < 0.001; rela-
tive risks compared to control cohort 3–8) included mood and
affective disorders, conduct disorders, speciﬁc developmental
disorders, including those of scholastic skills. Signiﬁcant associ-
ations (similar magnitude) were also found for ADHD and
adjustment disorders, habit and impulse disorders, tic disorders,
sleep disorders, disorders associated with sexual development,
maltreatment syndromes, mental retardation, lack of expected
normal physiological development and disorders due to brain
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ADHD in children and adolescents is associated with substantial
comorbidity. Longitudinal studies have shown ADHD to fre-
quently persist into adulthood. OBJECTIVES: To use adminis-
trative data from Nordbaden / Germany to assess the extent of
co-existing medical conditions in grown-ups with a diagnosis 
